NFKB1 and lymphoma: Although the anti-lymphoma effects of proteasome inhibitors and MLN4924 in GCB-DLBCL cells have shown to be primarily independent from NFκB inhibition [27–30], we first determined the effect of these drugs on the NFκB pathway in GCB-DLBCL cells.